UK markets closed

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.5600-0.0100 (-0.39%)
As of 12:45PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 78.58M
Enterprise value 114.75M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)54.25
Price/book (mrq)N/A
Enterprise value/revenue 83.15
Enterprise value/EBITDA -0.69

Trading information

Stock price history

Beta (5Y monthly) 0.39
52-week change 3-90.28%
S&P500 52-week change 322.38%
52-week high 329.5600
52-week low 31.9100
50-day moving average 32.8244
200-day moving average 33.7354

Share statistics

Avg vol (3-month) 31.48M
Avg vol (10-day) 3412.5k
Shares outstanding 530.58M
Implied shares outstanding 630.58M
Float 820.19M
% held by insiders 124.39%
% held by institutions 125.87%
Shares short (15 Apr 2024) 42.09M
Short ratio (15 Apr 2024) 44.08
Short % of float (15 Apr 2024) 423.64%
Short % of shares outstanding (15 Apr 2024) 46.83%
Shares short (prior month 15 Mar 2024) 43.14M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-5,285.90%

Management effectiveness

Return on assets (ttm)-74.95%
Return on equity (ttm)-1,766.94%

Income statement

Revenue (ttm)1.38M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)58.00%
Gross profit (ttm)N/A
EBITDA -167.3M
Net income avi to common (ttm)-179.05M
Diluted EPS (ttm)-6.1500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)65.22M
Total cash per share (mrq)2.13
Total debt (mrq)101.38M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.65
Book value per share (mrq)-1.89

Cash flow statement

Operating cash flow (ttm)-155.01M
Levered free cash flow (ttm)-96.55M